Genentech says drug combo reduces breast cancer recurrence

09/14/2005 | Forbes

Interim data from the company's Phase III trials indicates its Herceptin cancer drug used in combination with standard chemotherapy drugs reduced the risk of the disease returning by 39% to 51%, compared with chemotherapy by itself. The study involved 3,000 women with early-stage HER2-positive breast cancer, a type of cancer that accounts for about one in four breast cancers.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA